ERBB2 and breast cancer: A combined, prognostic score, including clinical variables, such as nodal status and perhaps tumor size, and molecular variables, such as optimized B-cell and IL-8 metagenes (measured by an RT-PCR or array-based method), may identify patients with very low risk of recurrence even with ER-, PgR- and HER2-negative breast cancer.